Syngenta signs exclusive EU deal for Amoéba biofungicide AXP20

Syngenta Crop Protection has signed an exclusive supply and distribution agreement with French biocontrol company Amoéba for a next-generation biofungicide, designated AXP20, across 27 EU member states, the United Kingdom, Ukraine and Switzerland. The deal converts a memorandum of understanding signed between the two companies in November 2025 into a long-term commercial and development partnership, with the product to be marketed under a Syngenta brand once regulatory approval is confirmed.

The product is formulated from a lysate of the single-celled amoeba Willaertia magna C2c Maky, which the European Food Safety Authority assessed and the EU approved as an active substance in 2025. In June 2026, Amoéba received a French market authorisation for AXPERA, a biofungicide based on the same technology, opening the path for national authorisations in other member states. First commercial approvals across the EU's major markets are targeted for the third quarter of 2028, with initial sales expected by end-2028 and farmer-level use from spring 2029, covering wheat, spelt and triticale.

The deal

Under the agreement, Syngenta holds exclusive distribution rights for all cereals except maize across the 31-country territory. The primary targets are the two most economically damaging fungal diseases in European cereal farming: Septoria leaf blotch (Zymoseptoria tritici) and yellow rust (Puccinia striiformis). Together, these diseases affect between nine and twelve million hectares each year. Septoria alone is reported to cause yield losses of five to fifty per cent in Germany, representing up to 1.5 billion euros annually for growers, while yellow rust can reduce yields by ten to seventy per cent and cause complete crop failure in susceptible varieties.

The partners said they are running more than 70 joint field trials in 2026, describing it as one of the largest development programmes in the biocontrol sector. The company did not disclose the financial terms of the supply agreement, including transfer pricing or milestone payments.

Matthew Pickard, head of Seedcare and Biologicals at Syngenta Europe, described the product as "a genuine breakthrough for our biocontrol portfolio and for every cereal grower looking to protect their yield and reinforce farm resilience."

Market context

The biocontrol market for cereal fungicides is expanding rapidly, driven by two structural forces: tightening EU pesticide regulation, which has removed or restricted a number of conventional active substances, and rising pathogen resistance to the remaining chemical options. AXP20's active ingredient is classified by the Fungicide Resistance Action Committee (FRAC) in group BM02, covering biological products with multiple modes of action and no known resistance. That multi-site activity positions it as a resistance-management tool as well as a standalone treatment.

Syngenta's move reflects a broader consolidation trend in agricultural biologicals, where large crop-protection companies are acquiring or partnering with smaller biocontrol developers to build out biological portfolios alongside synthetic chemistry. Rivals including BASF, Corteva and Bayer have made similar moves in the past three years. For Amoéba, a Euronext Growth-listed company, the Syngenta partnership provides commercial-scale distribution reach that a small specialist firm could not build independently.

Policy path

The regulatory backdrop is relevant to the commercial timeline. EU pesticide policy under the Farm to Fork framework has been setting more restrictive approval criteria for synthetic fungicides, while fast-tracking biological active substances that demonstrate a favourable environmental and resistance profile. The EFSA approval for Willaertia magna C2c Maky follows that pattern. The partnership will need to complete national-level product authorisations in each target market before first sales, a process that can be uneven across member states and could affect the 2028-29 commercial launch schedule.

Syngenta and Amoéba said the partnership also anticipates expansion to additional crops and geographies beyond the initial cereal focus as the efficacy profile of AXP20 broadens, positioning it as a long-term platform asset rather than a single-crop product.